Elucidation of the intricate interplay between SF3B1, ATM, and TP53 mutations is paramount for identifying novel therapeutic targets and for the stratification of patients with CLL into more refined prognostic categories. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.